GNI Group Ltd.
Gyre Therapeutics Submit Form S-3 Registration Statement｜June 2026
Gyre Therapeutics has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission to facilitate the sale of shares associated with the full acquisition of Cullgen. Currently, our holdings of Gyre shares are approximately 70%, and there is no expected impact on consolidated earnings.
Key Figures
- Gyre Shareholding Ratio: approximately 70%
- Form S-3 submission date of Gyre Therapeutics: June 23, 2026
- Complete date of consolidation of subsidiary: May 7, 2026
AI要約
Overview of Capital Policy and Stock Registration
Our consolidated subsidiary, Gyre Therapeutics, has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission. This procedure is related to the sale of shares following the full acquisition of Cullgen Inc. completed in May 2026. This submission is not intended as a new fundraising effort by Gyre but is a preparatory step to facilitate share sales. Currently, our effective ownership of Gyre shares is approximately 70%, and our holding policy remains unchanged.
Outlook and Impact
We do not anticipate any significant impact on our consolidated financial results from this matter. The share sale procedures for Gyre may contribute to improved stock liquidity and capital efficiency for shareholders and investors, but at this stage, the sale amount and schedule have not been disclosed. Going forward, we will continue to promote appropriate capital policies while monitoring Gyre’s management situation.
GNI Group
Company overview · Stock price · Financial data · All IR
